Not yet recruitingPhase 2NCT07499999
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
Studying Ataxia-telangiectasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Judy Garber, MD. MPHDana-Farber Cancer Institute
- Intervention
- Exemestane(drug)
- Enrollment
- 140 enrolled
- Eligibility
- FEMALE
- Timeline
- 2026 – 2028
Study locations (2)
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Breast Cancer Research Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07499999 on ClinicalTrials.govOther trials for Ataxia-telangiectasia
Additional recruiting or active studies for the same condition.